Abstract
Rationale
±3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") use is increasing around the globe but there is a paucity of studies examining the abuse liability of this drug.
Objectives
The ability of drugs to reinforce operant responding in laboratory animals is a valid and reliable predictor of abuse potential. MDMA is self-administered by humans, but there have been few reports of reliable self-administration by drug-naive laboratory animals. The present study sought to examine the acquisition and maintenance of MDMA self-administration by laboratory rats. The influence of prior training with cocaine self-administration on the acquisition of MDMA self-administration was also examined.
Methods
MDMA self-administration (0.25–2.0 mg/kg per infusion) was examined in rats that were first trained to self-administer cocaine as well as by those that were drug-naive. The dose-dependency of MDMA self-administration and the temporal pattern of responding maintained by various doses of MDMA were examined. In some rats, self-administration of MDMA during a 24-h session was also examined.
Results
MDMA was self-administered by laboratory rats that were experienced with self-administration of cocaine as well as by rats that were initially drug naive. For drug naive rats, the acquisition of MDMA self-administration (1.0 mg/kg per infusion) developed gradually during daily test sessions. The latency to acquisition of self-administration was shorter in cocaine-trained rats. Self-administration was dose-dependent, extinguished when saline was substituted for MDMA and, was reinstated when MDMA was reintroduced. During a 24-h self-administration session, a high rate of responding was produced during the first hour of the test session followed by a steady and lower rate of two to four responses per hour during subsequent hours of the test.
Conclusions
These results suggest that prior experience with cocaine self-administration facilitates the acquisition of MDMA self-administration. The results also suggest that MDMA has abuse liability and that increased use of the drug should raise concern of a growing and widespread potential for chronic abuse.
Similar content being viewed by others
References
Baker LE, Broadbent J, Michael EK, Matthews PK, Metosh CA, Saunders RB, West WB, Appel JB (1995) Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA). Behav Pharmacol 6:263–275
Bankson MG, Cunningham KA (2001) 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther 297:846–852
Bankson MG, Cunningham KA (2002) Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-HT1B/1D and 5-HT2 receptors. Neuropsychopharmacology 26:40–52
Beardsley PM, Balster RL, Harris LS (1986) Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alcohol Depend 18:149–157
Callaway CW, Geyer MA (1992) Tolerance and cross-tolerance to the activating effects of 3,4-methylenedioxymethamphetamine and a 5-hydroxytryptamine1B agonist. J Pharmacol Exp Ther 263:318–326
Callaway CW, Wing L, Geyer MA (1990) Serotonin release contributes to the stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 254:456–464
Carroll ME, Lac ST (1997) Acquisition of IV amphetamine and cocaine self-administration in rats as a function of dose. Psychopharmacology 129:206–214
De Deurwaerdere P, L'hirondel M, Bonhomme N, Lucas G, Cheramy A, Spaminato U (1997) Serotonin stimulation of 5-HT4 receptors indirectly enhances in vivo dopamine release in the rat. J Neurochem 68:195–203
Deneau G, Yanaghita T, Seevers MH (1969) Self-administration of psychoactive substances by the monkey. Psychopharmacologia 16:30–48
Fantegrossi WE, Ullrich T, Rice KC, Woods JH, Winger G (2002) 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology 161:356–364
Fischman MW, Schuster CR (1978) Drug seeking: a behavioral analysis in animals and humans. NIDA Res Monogr 20:4–23
Fletcher PJ, Robinson SR, Slippoy DL (2001) Pre-exposure to (±)3,4-methylenedioxymethamphetamine (MDMA) facilitates acquisition of intravenous cocaine self-administration in rats. Neuropsychopharmacology 25:195–203
Gudelsky GA, Yamamoto BK, Nash (1994) Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur J Pharmacol 264:325–330
Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE (2002) Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther 300:1093–1100
Hekmatpanah CR, Peroutka SJ (1990) 5-Hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methyenedioxymethamphetamine and related agents. Eur J Pharmacol 177:95–98
Hernandez-Lopez C, Farre M, Roset PN, Menoyo E, Pizarro N, Ortuno J, Torrens M, Cami J, de La Torre R (2002) 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 300:236–244
Herve D, Pickel VM, Joh TH, Beaudet A (1987) Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic terminals. Brain Res 435:71–83
Horan B, Gardner EL, Ashby CR Jr (2000) Enhancement of conditioned place preference response to cocaine in rats following subchronic administration of 3,4-methylenedioxymethamphetamine (MDMA). Synapse 35:160–162
Howell LL, Wilcox KM (2001) The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates. J Pharmacol Exp Ther 298:1–6
Iravani MM, Asari D, Patel J, Wieczorek WJ, Kruk ZL (2000) Direct effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphe nucleus slices. Synapse 36:275–285
Kalant H (2001) The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 165:917–928
Kalivas PW, Stewart J (1991) Dopamine transmission in the initiation and expression of drug- and stress-induced sensitisation to motor activity. Brain Res Rev 16:223–244
Kalivas PW, Duffy P, White SR (1998) MDMA elicits behavioral and neurochemical sensitization in rats. Neuropsychopharmacology 18:469–479
Kuhar MJ, Ritz M, Boja JW (1991) The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14:299–302
Lamb RJ, Griffiths RR (1987) Self-injection of d,1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology 91:268–272
Liechti ME, Vollenweider FX (2000) Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 10:289–295
Liechti ME, Vollenweider FX (2001) Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol Clin Exp 16:589–598
Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE (1991) MDL72222, a serotonin 5-HT3 receptor antagonist, blocks MDMA's ability to establish a conditioned place preference. Pharmacol Biochem Behav 39:509–512
Mayerhoffer A, Kovar K-A, Schmidt WJ (2001) Changes in serotonin, dopamine and noradrenaline levels in striatum and nucleus accumbens after repeated administration of the abused drug MDMA in rats. Neurosci Lett 308:99–102
McCreary AC, Bankson MG, Cunningham KA (1999) Pharmacological studies of the acute and chronic effects of (+)-3,4-methyenedioxymethamphetamine on locomotor activity: role of the 5-hydroxytryptamine1A and 5-hydroxytryptamine1B/1D receptors. J Pharmacol Exp Ther 290:965–973
Mello NK, Negus SS (1996) Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14:375–424
Metzger RR, Hanson GR, Gibb JW, Fleckenstein AE (1998) 3,4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function. Eur J Pharmacol 349:205–210
Nash JF, Brodkin J (1991) Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J Pharmacol Exp Ther 259:820–825
Ng N-K, Lee H-S, Wong PT-H (1999) Regulation of striatal dopamine release through 5-HT1 and 5-HT2 receptors. J Neurosci Res 55:600–607
Parrott AC (2002) Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71:837–844
Pederson W, Skrondal A (1999) Ecstasy and new patterns of drug use: a normal population study. Addiction 94:1695–1706
Piazza PV, Deminiere JM, Le Moal M, Simon H (1989) Factors that predict individual vulnerability to amphetamine self-administration. Science 245:1511
Pierre PJ, Vezina P (1997) Predisposition to self-administer amphetamine: the contribution of response to novelty and prior exposure to the drug. Psychopharmacology 129:277–284
Pope HG, Ionescu-Pioggia M, Pope KW (2001) Drug use and life style among college undergraduates: a 30-year longitudinal study. Am J Psychiatry 158:1519–1521
Ratzenboeck, E, Saria A, Kriechbaum N, Zernig G (2001) Reinforcing effects of MDMA ("ecstasy") in drug-naive and cocaine-trained rats. Pharmacology 62:138–144
Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396:157–198
Rothman RB, Baumann MH, Dersch ChM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32–41
Rudnick G, Wall S (1992) The molecular mechanism of "ecstasy" [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 89:1817–1821
Schenk S (2002) Sensitization as a process underlying the progression of drug use via "gateway" drugs. In: Kandel D (ed) Stages and pathways of drug involvement: examining the gateway hypothesis. Cambridge University Press, Cambridge, pp 318–336
Schenk S, Partridge B (1997) Sensitization and tolerance in psychostimulant self-administration. Pharmacol Biochem Behav 57:543–550
Schenk S, Partridge B (2000) Sensitization to cocaine's reinforcing effects produced by various cocaine pretreatment regimens in rats. Pharmacol Biochem Behav 66:765–770
Schenk S, Partridge B (2001) Influence of a conditioned light stimulus in cocaine self-administration. Psychopharmacology 154:390–396
Schenk S, Horger BA, Peltier R, Shelton K (1991) Supersensitivity to the reinforcing effects of cocaine following 6-hydroxydopamine lesions to the medial prefrontal cortex in rats. Brain Res 543:227–235
Schenk S, Valadez A, McNamara C, House D, Higley D, Bankson MT, Gibbs S, Horger BA (1993) Development and expression of sensitization to cocaine's reinforcing properties: role of NMDA receptors. Psychopharmacology 111:332–338
Schmidt CJ, Sullivan CK, Fadayel GN (1994) Blockade of striatal 5-HT2 receptors reduced the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem 62:1382–1389
Schuster CR, Thompson T (1969) Self administration of and behavioral dependence on drugs. Annu Rev Pharmacol 9:483–502
Schuster P, Lieb R, Lamertz C, Wittchen HU (1998) Is the use of ecstasy and hallucinogens increasing? Results from a community study. Eur Addict Res 4:75–82
Siliquini R, Faggiano F, Geninatti S, Versino E, Mitola B, Ippolito R (2001) Patterns of drug use among young men in Piedmont (Italy). Drug Alcohol Depend 64:329–335
Spanos LJ, Yamamoto BK (1989) Acute and subchronic effects of methylenedioxymethamphetamine [(±)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol Biochem Behav 32:835–840
Spruit IP (2001) Monitoring synthetic drug markets, trends, and public health. Subst Use Misuse 36:23–47
Teter CJ, Guthrie SK (2001) A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy 21:1486–1513
White SR, Obradovic T, Imel KM, Wheaton MJ (1996) The effects of methylenedioxymethamphetamine (MDMA,"Ecstasy") on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 49:455–479
Wise RA, Rompre P-P (1989) Brain dopamine and reward. Annu Rev Psychol 40:191–225
Yamamoto BK, Spanos J (1988) The acute effects of methylenedioxymethamphetamine on dopamine release in the awake behaving rat. Eur J Pharmacol 148:195–203
Yan QS, Yan SE (2001) Activation of 5-HT(1B/1D) receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: a microdialysis study. Eur J Pharmacol 418:55–64
Acknowledgements
This study was supported by research grants from Lottery Health, New Zealand, The Neurological Foundation of New Zealand and the University Research Fund, Victoria University of Wellington.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schenk, S., Gittings, D., Johnstone, M. et al. Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology 169, 21–27 (2003). https://doi.org/10.1007/s00213-003-1407-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-003-1407-0